SAVE THE DATE

15th International Congress on

LIQUID BIOPSY 2027

"Former ISMRC"

- Cancer Biology
- Cancer Evolution
- Early Cancer Detection
- Minimal Residual Disease (MRD)
- Disease Monitorization and RECIST-ctDNA
- Liquid Biopsy in Clinical Trials
- Multimodal Data Integration
- Emerging Technologies and Biomarkers
- Cancer Immunotherapy

12 - 14 MAY 2027

PALMA DE MALLORCA

VISIT THE WEBSITE

Co-chairs:

Rodrigo Toledo
Catherine Alix-Panabières
Klaus Pantel

Venue:

Auditorium Palma de Mallorca
Av. de Gabriel Roca, 18, Ponent

Organised by:

EUROPEAN LIQUID BIOPSY SOCIETY

PRELIMINARY SCIENTIFIC PROGRAMME

WEDNESDAY, MAY 12 2027

07:30 REGISTRATION

09:00-09:15 OPENING REMARKS

09:15-10:50 **SESSION 1. CANCER BIOLOGY**

09:15-09:40 **From the Pre-Metastatic Niche to liquid biopsy: the clinical potential of extracellular vesicles**
Héctor Peinado
Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

09:40-10:05 **Metabolic rewiring driving metastasis formation.**
Dr. Sarah-Maria Fendt
VIB Center for Cancer Biology, KU Leuven, Belgium

10:05-10:30 **Gut dysbiosis is a risk factor in immunooncology.**
Dr. Laurence Zitvogel
Gustave Roussy, Université Paris Saclay, Paris, France

10:30-10:40 **Selected Oral Communication 1**

10:40-10:50 **Selected Oral Communication 2**

10:50 – 11:30 COFFEE BREAK · POSTER VIEWING · NETWORKING

11:30-13:00 **SESSION 2. CANCER EVOLUTION**

11:30-11:55 **Tracking cancer evolution and designing disease interception using ultrasensitive ctDNA analysis.**
Dr. Alexander Frankell, CRUK Cambridge Centre and University of Cambridge, UK

11:55-12:20 *Slot reserved to Liquid Biopsy Hot Topic*

12:20-12:45 **The role of phenotypic diversity and functional networks of CTC clusters during metastatic spread.**
Dr. Frédéric Thomas
Centre national de la recherche scientifique, Paris, France

12:45-12:55 **Selected Oral Communication 3**

12:55-13:05 **Selected Oral Communication 4**

13:05-14:30 LUNCH BREAK · POSTER SESSION · NETWORKING

14:30-16:30 **SESSION 3. EMERGING TECHNOLOGIES AND BIOMARKERS**

14:30-14:55 **miRacles in cancer**
Dr. George A. Calin
UT MD Anderson, Houston, Texas, USA

14:55-15:20 **TCR repertoire and longitudinal TCR-sequencing as a blood biomarker for patients treated with immunotherapy.**
TBC

15:20-15:45 **Cerebrospinal Fluid for Brain Tumor Characterization and Monitoring**
Dr. Joan Seoane
Vall d'Hebron Institute of Technology, Barcelona, Spain

15:45-16:10 **Deciphering prostate cancer dynamics using extracellular vesicles.**
Francesca Demicaelis
University of Trento, Italy

16:10-16:20 **Selected Oral Communication 5**

16:20-16:30 **Selected Oral Communication 6**

16:30-18:05 SESSION 4. EARLY CANCER DETECTION

16:30-16:55 **Early detection of circulating mutations.**
Dr. Nickolas Papadopoulos
Johns Hopkins University School of Medicine, New York, USA

16:55-17:20 **New technologies for enhanced ctDNA detection.**
Dr. Viktor A. Adalsteinsson
Gerstner Center for Cancer Diagnostics, Broad Institute of MIT, Harvard, Cambridge, Massachusetts, USA

17:20-17:45 **Deciphering methylation profiles from plasma-based ctDNA for early tumor detection.**
Dr. Daniel de Carvalho
Princess Margaret Cancer Center, Toronto, Canada

17:45-17:55 **Selected Oral Communication 7**

17:55-18:05 **Selected Oral Communication 8**

18:05 -19:15 POSTER SESSION AND NETWORKING

21:00 WELCOME RECEPTION

THURSDAY, MAY 13 2027

09:00-10:10 SESSION 5. MINIMAL RESIDUAL DISEASE

09:00-09:25 **Updates on the PANCAID and GUIDE.MRD projects: current status and future perspectives**
Dr. Klaus Pantel
Institute of Tumour Biology and University Medical Centre Hamburg-Eppendorf, Germany

09:25-09:50 **ctDNA-MRD testing to guide adjuvant therapy in early-stage colorectal cancer**
Dr. Clara Montagut
Hospital del Mar, Barcelona, Spain

09:50-10:00 **Selected Oral Communication 9**

10:00-10:10 **Selected Oral Communication 10**

10:10 – 10:40 COFFEE BREAK AND POSTER VIEWING - NETWORKING

10:40-12:50 SESSION 6. CLINICAL TRIALS

10:40-11:05 **CT-scan RECIST vs ctDNA-RECIST in advanced lung cancer treatment with first-line immunotherapy: the PRELUCA study**
Dr. Malene Støchkel Frank
Zealand University Hospital, Roskilde, Denmark

11:05-11:30 **Incorporation of liquid biopsy in randomized clinical trials: past, present, and future.**
Dr. Silvia Marsoni
IFOM Istituto Fondazione di Oncologia Molecolare ETS, Milano, Italy

11:30-11:55 **Recent advances in ctDNA-guided bladder cancer management: lessons learned and incorporation into clinical guidelines**
Dr. Lars Dyrskjøt
Department of Clinical Medicine, Aarhus University, Denmark

11:55-12:20 Slot reserved to Liquid Biopsy Hot Topic

12:20-12:30 **Selected Oral Communication 11**

12:30-12:40 **Selected Oral Communication 12**

12:40-12:50 **Selected Oral Communication 13**

12:50-14:15 LUNCH AND POSTER SESSION – NETWORKING

14:15-15:25 SESSION 7. IMMUNOTHERAPY

14:15-14:40 **The Next Generation of Liquid Biopsy: Multi-Omics for Precision Immuno-Oncology**
Dr. Catherine Alix-Panabières
Centre Hospitalier Universitaire de Montpellier, France

14:40-15:05 **The search for the ideal tumor-blood biomarker for Cancer Immunotherapy**
Dr. Paul Hofman
Liquid Biopsy Centre, Nice, France

15:05-15:15 **Selected Oral Communication 14**

15:15-15:25 **Selected Oral Communication 15**

15:25-17:25 SESSION 8. DISEASE MONITORIZATION AND RECIST ctDNA

15:25-15:50 **Use of real time ctDNA to guide therapy switch**
Dr. Caroline Dive
Cancer Research UK National Biomarker Centre, Manchester, UK

15:50-16:15 **Can we ctDNA-RECIST? Lessons from ongoing randomized interventional trials.**
Dr. Karen-Lise Garm Spindler
Aarhus University Hospital, Denmark

16:15-16:40 **Multimodal ctDNA derivatives for RECIST-ctDNA in the context of early clinical trials.**
Dr. Rodrigo Toledo
Vall d'Hebron Institute of Oncology, Barcelona, Spain

16:40-17:05 **Beyond mutation-based ctDNA for assessing therapy response and disease monitoring**
Dr. Julia Burnier
McGill University Health Centre, Montreal, Canada

17:05-17:15 **Selected Oral Communication 16**

17:15-17:25 **Selected Oral Communication 17**

17:25-18:45 POSTER SESSION - NETWORKING

20:00 GALA DINNER

FRIDAY, MAY 14 2027

08:45 -09:30 SESSION 9. LATEST DEVELOPMENTS (Diamond & Platinum Sponsors)

08:45-09:00 **Lecture – TBD (Technologies/Biomarkers)**

09:00-09:15 **Lecture – TBD (Neo Adj, Adj)**

09:15-09:30 **Lecture – TBD**

09:30-10:40 SESSION 10. MULTIMODAL LBx DATA INTEGRATION

09:30-09:55 **AI for integrating multimodal liquid biopsy into routine clinical practice**
Dr. Nuria Malats
Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

09:50-10:20 **TCR repertoire from cell-free DNA: a new multimodal liquid biopsy component**
Dr. Trevor J. Pugh
Ontario Institute Cancer Research, Canada

10:20-10:30 **Selected Oral Communication 18**

10:30-10:40 **Selected Oral Communication 19**

10:40 – 11:10 COFFEE BREAK

11:10-12:20 SESSION 11. INMUNOTHERAPY

11:10-11:35 **Plasma-based ctDNA fragmentomics for predicting response to immune checkpoint inhibitors**
Dr. Valsamo Anagnostou
Johns Hopkins University School of Medicine, Baltimore, USA

11:35-12:00 **Multimodal liquid biopsy biomarkers for cancer immunotherapy**
Dr. Rafael López
Complexo Hospitalario Universitario de Santiago de Compostela, Spain

12:00-12:10 **Selected Oral Communication 20**

12:10-12:20 **Selected Oral Communication 21**

12:20-13:20 SESSION 12. REGULATORY & REIMBURSEMENT

13:20-13:30 Young Investigator Awards

13:30-13:45 Concluding remarks